We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of Angiotensin II in Insulin-induced Microvascular Activity

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01024543
First Posted: December 2, 2009
Last Update Posted: December 2, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Maastricht University Medical Center
  Purpose
In this study we hypothesize infusion of Angiotensin II improves the insulin-induced microvascular dilatation and therefore insulin-mediated glucose uptake. Objectives: Does infusion of Angiotensin II increase insulin-mediated glucose uptake via enhanced insulin-mediated microvascular function in healthy subjects?

Condition Intervention
Insulin Sensitivity Microcirculation Drug: Angiotensin II Drug: Phenylephrine Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Role of Angiotensin II in Insulin-induced Microvascular Activity

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • functional recruitment of capillaries in the skin [ Time Frame: January 2009 ]

Secondary Outcome Measures:
  • perfused capillary density in the nailfold [ Time Frame: January 2009 ]
  • Endothelium- (in)dependent vasodilatation of finger skin microcirculation [ Time Frame: January 2006 ]
  • Insulin sensitivity [ Time Frame: January 2009 ]

Enrollment: 18
Study Start Date: October 2006
Estimated Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: Placebo
Placebo
Drug: Placebo
Experimental: Angiotensin II
Angiotensin II
Drug: Angiotensin II
Angiotensin II
Active Comparator: Phenylephrine
Phenylephrine
Drug: Phenylephrine
Phenylephrine

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

1.18-60 years 2.Caucasian 3.Blood pressure <140/90 mmHg.

Exclusion Criteria:

  1. Obesity (BMI>27kg/m2)
  2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
  3. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
  4. Smoking
  5. Alcohol use >4U/day
  6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
  7. Pregnancy
  8. Wearing contact lenses
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01024543


Locations
Netherlands
Maastricht University Medical Centre
Maastricht, P.o. Box 5800, Netherlands, Netherlands, 6202 AZ
Sponsors and Collaborators
Maastricht University Medical Center
Investigators
Study Chair: CDA Stehouwer, Prof Maastricht University Medical Centre
  More Information

Responsible Party: Prof. CDA Stehouwer, Maastricht University Medical Centre
ClinicalTrials.gov Identifier: NCT01024543     History of Changes
Other Study ID Numbers: MEC 06-2-074
First Submitted: November 30, 2009
First Posted: December 2, 2009
Last Update Posted: December 2, 2009
Last Verified: December 2009

Keywords provided by Maastricht University Medical Center:
Angiotensin II

Additional relevant MeSH terms:
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Phenylephrine
Oxymetazoline
Angiotensin II
Angiotensinogen
Cardiotonic Agents
Mydriatics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sympathomimetics
Vasoconstrictor Agents
Nasal Decongestants
Respiratory System Agents
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors